Advertisement

European Society for Medical Oncology 2023: eNSCLC

Can Radiotracers Predict Response to PD-L1 Inhibitors in Early NSCLC?

Nov 14, 2023

REFERENCES & ADDITIONAL READING

Felip E, Altorki N, Zhou C, et al; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357.

 

O’Brien M, Paz-Ares L, Marreaud S, et al; EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-1286.

 

Hughes DJ, Subesinghe M, Taylor B, et al. 18F FDG PET/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology. 2022 Aug;304(2):246-264.

 

Nazir MS, Hughes DJ, Chand G, et al; PECan study group. [99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression. EJNMMI Res. 2023 May 17;13(1):44.

ABOUT THE EXPERTS

  • Gary Cook, MBBS, MSc, MD, FRCR, FRCP

    Professor of Molecular Imaging Harvey & Bernice Jones Eye Institute
    King’s College London
    Honorary Consultant Medicine Physician
    Guy’s and St. Thomas Hospitals
    United Kingdom

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement